Journal of Diabetes and Its Complications
Volume 15, Issue 6 , Pages 295-300 , November 2001

A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump

  • Philip Raskin

      Affiliations

    • Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, G5-238, Dallas, TX 75390-8858, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-214-648-2017; fax: +1-214-648-4854
    • ,
  • John H Holcombe

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    • ,
  • William V Tamborlane

      Affiliations

    • Section of Pediatric Endocrinology, Yale University School of Medicine, PO Box 208064, 33 Cedar St., New Haven, CT 06520-8064, USA
    • ,
  • John I Malone

      Affiliations

    • Department of Pediatrics, College of Medicine, University of South Florida, 4202 E. Fowler Ave., Tampa, FL, USA
    • ,
  • Suzanne Strowig

      Affiliations

    • Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, G5-238, Dallas, TX 75390-8858, USA
    • ,
  • Jo Ann Ahern

      Affiliations

    • Section of Pediatric Endocrinology, Yale University School of Medicine, PO Box 208064, 33 Cedar St., New Haven, CT 06520-8064, USA
    • ,
  • Francine Lavent

      Affiliations

    • Department of Pediatrics, College of Medicine, University of South Florida, 4202 E. Fowler Ave., Tampa, FL, USA

Received 24 May 2001 ,Accepted 20 June 2001.

References 

  1. Anderson JH, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, et al. Reduction of post-prandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes. 1997;46:265–270
  2. Attia N, Jones TW, Holcombe JH, Tamborlane WV. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care. 1998;21:817–821
  3. Bode BW, Steed RD, Davidson PC. Continuous subcutaneous insulin infusion (CSII): a study comparing lispro to regular human insulin. Diabetes. 1997;46(Suppl. 1):167A
  4. Brunelle RL, Llewelyn J, Anderson JH, Gale EAM, Koivisto VA. Metaanalysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care. 1998;21:1726–1731
  5. Campbell RK, Sclar DA, Robison LM, Stowers JK, Ferguson JC, Trippe BS, et al. Impact on clinical status and quality of life of switching from regular human insulin to insulin lispro among patients using insulin pumps. Diabetes Educator. 1998;24:95–99
  6. The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. New England Journal of Medicine. 1993;329:977–986
  7. The Diabetes Control and Complications Trial Research Group . The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968–983
  8. Ebeling P, Jansson P-A, Smith U, Lalli C, Bolli GB, Koivisto VA. Strategies toward improved control during insulin lispro therapy in IDDM: importance of basal insulin. Diabetes Care. 1997;20:1287–1289
  9. Guerci B, Meyer L, Sallé A, Charrié A, Dousset B, Ziegler O, et al. Comparison of metabolic deterioration between insulin analog and regular human insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. Journal of Clinical Endocrinology and Metabolism. 1999;84:2673–2678
  10. Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AA, et al. Prandial glycaemia after a carbohydrate-rich meal in Type I diabetic patients: using the rapid acting insulin analogue [Lys (28) Pro (B29)] human insulin. Diabetic Medicine. 1996;13:625–629
  11. Hirsch IB, Farkas-Hirsch R, McGill JB. Catheter obstruction with continuous subcutaneous insulin infusion: effect of insulin concentration. Diabetes Care. 1992;15:593–594
  12. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys (B28), Pro (B29)] Human insulin: a rapidly absorbed analogue of human insulin. Diabetes. 1994;43:396–402
  13. Koivisto VA. The human insulin analogue insulin lispro. Annals of Medicine. 1998;30:260–266
  14. Lins PE, Johansson UB, Wredling R, Adamson U. Blood glucose variability and well-being during CSII using insulin lispro and regular human insulin. abstract Diabetes. 1998;47(Suppl. 1):39A
  15. Mecklenburg RS, Benson JW, Becker NM, Brazel PL, Fredlund PN, Metz RJ, et al. Clinical use of the insulin infusion pump in 100 patients with Type 1 diabetes. New England Journal of Medicine. 1982;307:513–518
  16. Melki V, Renard E, Lassmann-Vague V, Boivin S, Guerci B, Hanaire-Broutin H, et al. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care. 1998;21:977–982
  17. Pampanelli S, Torlone E, Lalli E, Del Sindaco P, Ciofetta M, Lepore M, et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic-cell function. Diabetes Care. 1995;18:1452–1459
  18. The WHO classification of diabetes. In:  Pickup JC,  Williams G editor. Textbook of diabetes. Oxford, England: Blackwell Scientific Publications; 1991;p. 39
  19. Ratner RE, Steiner ML. Insulin-pump therapy: effect of phosphate-buffered human insulin. Diabetes Care. 1987;10:787–788
  20. Reichel A, Rietzsch H, Kohler HJ, Pfützner A, Gudat U, Schulze J. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro. Experimental and Clinical Endocrinology & Diabetes. 1998;106:168–172
  21. Renner R, Pfützner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Diabetes Care. 1999;22:784–788
  22. Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. New England Journal of Medicine. 1979;300:573–578
  23. Tuominen JA, Karonen SL, Melamies L, Bolli G, Koivisto VA. Exercise induced hypoglycaemia in IDDM patients treated with short-acting insulin analogue. Diabetologia. 1995;38:106–111
  24. Zinman B, Tildesley H, Chiasson J-L, Tsui E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes. 1997;46:440–443

☆ Eli Lilly sponsored this research.

PII: S1056-8727(01)00168-4

Journal of Diabetes and Its Complications
Volume 15, Issue 6 , Pages 295-300 , November 2001

Article Tools

* Image Usage & Resolution